Modern Brachytherapy for Treatment of Prostate Cancer

Abstract

Background

Prostate cancer is the most common cancer diagnosed in men. An increasing number of these patients are seeking minimally invasive procedures such as transperineal interstitial permanent radioactive seed prostate brachytherapy.

Methods

This paper reviews the historical perspective and the current advances in transperineal interstitial permanent radioactive seed prostate brachytherapy. The 10- to 15-year results data now published for brachytherapy alone or in combination with external-beam irradiation are also reviewed.

Results

Modern brachytherapy using transperineal interstitial permanent radioactive seed prostate brachytherapy offers patients an excellent quality of life with convenient outpatient treatment with long-term (10- to 15-year) biochemical relapse-free survival rates ranging from 67% to 87%, depending on risk stratification.

Conclusions

Modern-day brachytherapy utilizing either radioactive iodine-125 or palladium-103 alone or in combination with supplemental external-beam treatment offers patients a successful treatment outcome with acceptable toxicity.

References

Jemal

, Siegel

, Ward

. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43–66.

Cooperberg

M.R.

, Lubeck

D.P.

, Meng

M.V.

. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141–2149.

O'Leary

M.P.

, Baum

N.H.

, Blizzard

. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002; 168: 649–652.

Scardino

, Carlton

. Combined interstitial and external irradiation for prostatic cancer. In: Javadpour

, ed. Principles and Management of Urologic Cancer. Baltimore, Md: Williams & Wilkins; 1983: 392–408.

Whitmore

W.F.

Jr , Hilaris

, Grabstald

. Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol. 1972; 108: 918–920.

Hilaris

, Fuks

, Nori

. Interstitial irradiation and prostate cancer: report of ten-year results. In: Gerhart

, Sauer

, eds. Interventional Radiation Therapy Techniques/Brachytherapy. Berlin, Germany: Springer-Verlag; 1991.

Holm

H.H.

, Juul

, Pedersen

J.F.

. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983; 130: 283–286.

Blasko

J.C.

, Ragde

, Schumacher

. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurietherapy Hyperthermia Oncol. 1987; 3: 131–139.

Grimm

P.D.

, Blasko

J.C.

, Sylvester

J.E.

. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachyther-apy. Int J Radiat Oncol Biol Phys. 2001; 51: 31–40.

10.

Potters

, Morgenstern

, Calugaru

. 12 year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005; 173: 1562–1566.

11.

Sylvester

J.E.

, Grimm

P.D.

, Blasko

J.C.

. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007; 67: 57–64. Epub 2006 Nov 2.

12.

Lawton

C.A.

, DeSilvio

, Lee

W.R.

. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007; 67: 39–47. Epub 2006 Nov 2.

13.

Potters

, Cao

, Calugaru

. A comprehensive review of CTbased dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001; 50: 605–614.

14.

Stock

R.G.

, Stone

N.N.

, Lo

Y.C.

. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 2000; 48: 899–906.

15.

Wallner

, Merrick

, True

. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003; 57: 1297–1303.

16.

Heysek

R.V.

, Gwede

C.K.

, Torres-Roca

. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 2006; 5: 244–250.

17.

Tapen

E.M.

, Blasko

J.C.

, Grimm

P.D.

. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998; 42: 1063–1067.

18.

Merrick

G.S.

, Butler

W.M.

, Dorsey

A.T.

. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000; 46: 215–220.

19.

Shanahan

T.G.

, Mueller

P.W.

, Roszhart

D.A.

. Image guided I125 prostate brachytherapy with Hybrid Interactive Mick technique in the community setting: how does it compare? Technol Cancer Res Treat. 2004; 3: 209–215.

20.

Eshleman

J.S.

, Davis

B.J.

, Pisansky

T.M.

. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004; 59: 419–425.

21.

Davis

B.J.

, Bresnahan

J.F.

, Stafford

S.L.

. Prostate brachytherapy seed migration to a coronary artery found during angiography. J Urol. 2002; 168: 1103.

22.

Zhu

A.X.

, Wallner

K.E.

, Frivold

G.P.

. Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy. 2006; 5: 262–265.

23.

Narayana

, Troyer

, Evans

. Randomized trial of high- and low-source strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys. 2005; 61: 44–51.

24.

Fisch

B.M.

, Pickett

, Weinberg

. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology. 2001; 57: 955–959.

25.

Roach

, Winter

, Michalski

J.M.

. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II doseescalation study. Int J Radiat Oncol Biol Phys. 2004; 60: 1351–1356.

26.

Langley

S.E.M.

. Permanent low-dose-rate prostate brachytherapy. Eur Oncol Dis. 2006; 1: 59–63

27.

Stock

R.G.

, Kao

, Stone

N.N.

. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol. 2001; 165: 436–439.

28.

Zelefsky

M.J.

, Yamada

, Cohen

G.N.

. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 65–70.

29.

Zelefsky

M.J.

, Yamada

, Cohen

. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys. 2000; 48: 601–608.

30.

Nag

, Ciezki

J.P.

, Cormack

. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2001; 51: 1422–1430.

31.

Zaider

, Zelefsky

M.J.

, Lee

E.K.

. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2000; 47: 1085–1096.

32.

Wallner

, Merrick

, True

. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003; 57: 1297–1303.

33.

Nath

, Roberts

, Ng

. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys. 1998; 25: 2293–2307.

34.

Ling

C.C.

. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys. 1992; 23: 81–87.

35.

Anderson

L.L.

, Moni

J.V.

, Harrison

L.B.

. A nomograph for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys. 1993; 27: 129–135.

36.

Wallner

, Merrick

, True

. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J. 2002; 8: 67–73.

37.

Wallner

, Merrick

, True

. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003; 57: 1297–1303.

38.

Warren General Hospital introduces promising Cesium-131 isotope for treating prostate cancer; local resident will be the first in the northeast using IsoRay Medical's breakthrough treatment option.

Business Wire. June 28, 2005. Available at http://www.encyclopedia.com/doc/1G1-133610376.html. Accessed April 5, 2007.

39.

Roach

III , Hanks

, Thames

Jr ,. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965–974.

40.

Fitch

D.L.

, McGrath

, Martinez

A.A.

. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Int J Radiat Oncol Biol Phys. 2006; 66: 1430–1439. Epub 2006 Jun 12.

41.

D'Amico

A.V.

, Moul

, Carroll

P.R.

. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003; 21: 2163–2172.